Published in Am J Ophthalmol on January 21, 2016
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy (LRTforDME+PRP) | NCT00445003
Update on corticosteroids for diabetic macular edema. Clin Ophthalmol (2016) 0.83
Current Challenges in Diabetic Retinopathy: Are We Really Doing Better? Endocrinol Metab (Seoul) (2016) 0.77
Initiation of intravitreal aflibercept injection treatment in patients with diabetic macular edema: a review of VIVID-DME and VISTA-DME data. Int J Retina Vitreous (2016) 0.75
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99
Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology (2014) 1.49
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology (2014) 1.30
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol (2014) 4.34
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA (2015) 2.78
Assessing the Effect of Personalized Diabetes Risk Assessments During Ophthalmologic Visits on Glycemic Control: A Randomized Clinical Trial. JAMA Ophthalmol (2015) 2.12
Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol (2009) 2.06
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology (2016) 2.04
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina (2015) 1.99
Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol (2008) 1.87
Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol (2009) 1.72
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol (2008) 1.47
Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment. JAMA Ophthalmol (2016) 1.47
Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol (2012) 1.47
Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema. JAMA Ophthalmol (2016) 1.44
A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina (2008) 1.43
A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology (2010) 1.34
Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology (2014) 1.30
Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study. Ophthalmology (2007) 1.25
Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci (2012) 1.17
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol (2009) 1.13
Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology (2010) 1.13
Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol (2012) 1.01
Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. Retina (2009) 1.01
The course of response to focal/grid photocoagulation for diabetic macular edema. Retina (2009) 0.99
Visual acuity testing using autorefraction or pinhole occluder compared with a manual protocol refraction in individuals with diabetes. Ophthalmology (2010) 0.94
Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol (2015) 0.92
Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol (2013) 0.91
Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. Invest Ophthalmol Vis Sci (2011) 0.89
Association of the extent of diabetic macular edema as assessed by optical coherence tomography with visual acuity and retinal outcome variables. Retina (2009) 0.88
Ocular side effects associated with peribulbar injections of triamcinolone acetonide for diabetic macular edema. Retina (2011) 0.88
Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol (2015) 0.86
Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol (2014) 0.85
A Phase 1 Study of Intravitreous E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. Ophthalmology (2015) 0.84
Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial. JAMA Ophthalmol (2016) 0.82
Green or yellow laser treatment for diabetic macular edema: exploratory assessment within the Diabetic Retinopathy Clinical Research Network. Retina (2013) 0.81
Bullous Variant of Central Serous Chorioretinopathy: Expansion of Phenotypic Features Using Multimethod Imaging. Ophthalmology (2016) 0.81
Topical nepafenec in eyes with noncentral diabetic macular edema. Retina (2015) 0.80
Evaluation of visual acuity measurements after autorefraction vs manual refraction in eyes with and without diabetic macular edema. Arch Ophthalmol (2011) 0.79
Keeping the Name of Acute Posterior Multifocal Placoid Pigment Epitheliopathy. JAMA Ophthalmol (2017) 0.79
Ebola and the Eye. JAMA Ophthalmol (2015) 0.78
Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial. JAMA Ophthalmol (2016) 0.78
Revolution to a new standard treatment of diabetic macular edema. JAMA (2014) 0.77
Evaluation of masking study participants to intravitreal injections in a randomized clinical trial. Arch Ophthalmol (2012) 0.75
Effects of dilation on electronic-ETDRS visual acuity in diabetic patients. Invest Ophthalmol Vis Sci (2008) 0.75
Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Am J Ophthalmol (2016) 0.75
Measurement and Reproducibility of Preserved Ellipsoid Zone Area and Preserved RPE Area in a Cohort of Eyes with Choroideremia. Am J Ophthalmol (2017) 0.75
Melvin L. Rubin, MD (1932-2014). JAMA Ophthalmol (2014) 0.75
Long-term Contributions From the Diabetes Control and Complications Trial Cohort. JAMA Ophthalmol (2015) 0.75
En Face Optical Coherence Tomography Analysis to Assess the Spectrum of Perivenular Ischemia and Paracentral Acute Middle Maculopathy in Retinal Vein Occlusion. Am J Ophthalmol (2017) 0.75
Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. JAMA Ophthalmol (2017) 0.75
Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology (2017) 0.75
Reply. Ophthalmology (2017) 0.75
Reply. Ophthalmology (2017) 0.75
Elimination of Topical Antibiotics for Intravitreous Injections and the Importance of Using Povidone-Iodine: Update From the Diabetic Retinopathy Clinical Research Network. JAMA Ophthalmol (2016) 0.75
Reply. Am J Ophthalmol (2017) 0.75
Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study). Ophthalmology (2020) 0.75
Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial. JAMA Ophthalmol (2017) 0.75
Reply. Ophthalmology (2017) 0.75
Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial. JAMA Ophthalmol (2017) 0.75